Neoantigen srRNA Vaccine JCXH-212

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer vaccine consisting of self-replicating RNA (srRNA) encoding a patient's tumor-specific neoantigens, with potential immunomodulatory and antineoplastic activities. Upon administration of neoantigen srRNA vaccine JCXH-212, the srRNA is taken up by and translated into the neoantigens in the patient's antigen-presenting cells (APCs), primarily dendritic cells (DCs), and presented by major histocompatibility complex (MHC) molecules on the surface of the APCs. This may activate tumor antigen-specific T-cells to kill cancer cells expressing these neoantigens.

**Synonyms:** - JCXH 212 - JCXH-212 - JCXH212 - Vaccine JCXH-212